scholarly article | Q13442814 |
P356 | DOI | 10.1001/ARCHINTE.162.8.921 |
P698 | PubMed publication ID | 11966344 |
P50 | author | Sue Goldie | Q7634103 |
Milton Weinstein | Q30223679 | ||
Elena Losina | Q55523364 | ||
A. David Paltiel | Q58704489 | ||
Kenneth A. Freedberg | Q87347438 | ||
George Seage | Q90086356 | ||
April D. Kimmel | Q90776420 | ||
P2093 | author name string | Hong Zhang | |
Donald E Craven | |||
Jonathan E Kaplan | |||
Calvin J Cohen | |||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pneumonia | Q12192 |
Pneumocystis carinii | Q2099992 | ||
P304 | page(s) | 921-928 | |
P577 | publication date | 2002-04-01 | |
P1433 | published in | JAMA Internal Medicine | Q177428 |
P1476 | title | Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines | |
P478 | volume | 162 |
Q33636804 | A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing |
Q37023469 | A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy |
Q37259653 | Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives |
Q59353398 | Autoimmune blistering disorders in the setting of human immunodeficiency virus infection |
Q36628019 | Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy |
Q34020879 | Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine. |
Q36628399 | Cost-effectiveness of HIV testing and treatment in the United States |
Q35692811 | Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease. |
Q44509935 | Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection |
Q35575721 | Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India |
Q24245223 | Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole |
Q24245408 | Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole |
Q47968071 | Dapsone-Induced Acute Pancreatitis |
Q35967212 | Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database |
Q38898943 | Modeling the cost-effectiveness of health programs: HIV testing and early treatment in the USA. |
Q44255331 | Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. |
Q36948496 | Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care |
Q34423942 | The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa |
Q31082790 | The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis |
Q47431983 | Utilities Derived from Visual Analog Scale Scores in Patients with HIV/AIDS |
Q44261958 | Variations in self-rated health among patients with HIV infection |
Search more.